---
title: "Bezuclastinib in Gastrointestinal stromal tumor: Terms and abbreviations"
description: "Formulary evidence on Bezuclastinib in Gastrointestinal stromal tumor: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/terms-and-abbreviations"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Bezuclastinib in Gastrointestinal stromal tumor: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| AE | Adverse event |
| AL | Activation loop |
| ALT | Alanine aminotransferase |
| AP | ATP-binding pocket |
| ASCO | American Society of Clinical Oncology |
| AST | Aspartate aminotransferase |
| ATP | Adenosine triphosphate |
| AUC | Area under the concentration-time curve |
| AUCss | Area under the concentration-time curve at steady state |
| BICR | Blinded independent central review |
| BTD | Breakthrough Therapy Designation |
| CAS | Chemical Abstracts Service |
| CBR | Clinical benefit rate |
| CI | Confidence interval |
| CR | Complete response |
| ctDNA | Circulating tumor DNA |
| CTOS | Connective Tissue Oncology Society |
| CYP3A4 | Cytochrome P450 3A4 |
| DLT | Dose-limiting toxicity |
| ECOG | Eastern Cooperative Oncology Group |
| FDA | U.S. Food and Drug Administration |
| GEIS | Spanish Group for Research on Sarcomas |
| GI | Gastrointestinal |
| GIST | Gastrointestinal stromal tumor |
| HR | Hazard ratio |
| HRQoL | Health-related quality of life |
| KIT | KIT receptor tyrosine kinase |
| mPFS | Median progression-free survival |
| mRECIST | Modified Response Evaluation Criteria in Solid Tumors |
| MTD | Maximum tolerated dose |
| mTOR | Mechanistic target of rapamycin |
| NCCN | National Comprehensive Cancer Network |
| NDA | New drug application |
| NTRK | Neurotrophic receptor tyrosine kinase |
| ORR | Objective response rate |
| OS | Overall survival |
| PD | Progressive disease |
| PDGFR | Platelet-derived growth factor receptor |
| PDGFRA | Platelet-derived growth factor receptor alpha |
| PDUFA | Prescription Drug User Fee Act |
| PFS | Progression-free survival |
| PK | Pharmacokinetics |
| PR | Partial response |
| QALY | Quality-adjusted life-year |
| QD | Once daily |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| RP2D | Recommended phase 2 dose |
| RTOR | Real-Time Oncology Review |
| SCF | Stem cell factor |
| SCFR | Stem cell factor receptor |
| SD | Stable disease or standard deviation, according to context |
| TKI | Tyrosine kinase inhibitor |
| TRAE | Treatment-related adverse event |
| TRK | Tropomyosin receptor kinase |

## Related pages
- [Bezuclastinib: Gastrointestinal stromal tumor](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor.md)
- [Bezuclastinib: Gastrointestinal stromal tumor](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/executive-summary) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/executive-summary.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Product information and disease description](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/product-information-and-disease-description.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Clinical evidence](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/clinical-evidence.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Economic information and modeling report](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/economics) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/economics.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: References](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/references) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/references.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: prevalence by geography](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/prevalence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/prevalence.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/cost-effectiveness-analyses.md)
